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Iguratimod (IGU, also known as T-614), a novel disease modifying antirheumatic drug intended to cure 
patients with rheumatoid arthritis (RA). The purpose of this study is to evaluate the effect of IGU on 
the pharmacokinetics of CYP2C9 probe drug diclofenac and its metabolite 4′-hydroxy diclofenac in 
vivo and in vitro. In in vivo experiments, 24 rats were randomly assigned to three groups consisting of 
the control group (Normal saline), low dose IGU group (10 mg/kg) and high dose IGU group (30 mg/
kg). Blood samples were collected from orbital sinuses vein before 1 hour and serial times of giving 
diclofenac (15 mg/kg) to all the rats. Plasma concentration of diclofenac and its metabolite 4´-hydroxy 
diclofenac were assayed by high performance liquid chromatography. Pharmacokinetic parameters 
were assessed by Winnonlin 6.4 pharmacokinetic software. Moreover, in vitro studies were performed 
in recombinant human CYP2C9 yeast cell system. IGU at low dose showed no significant differences 
in the pharmacokinetic parameters of diclofenac and 4-hydroxy diclofenac in vivo when compared with 
control group (p>0.005). However, at the high dose of IGU, the pharmacokinetic parameters of 4´-hydroxy 
metabolite of diclofenac increase in half-life (T1/2) and mean area under the curve (AUC0→24), while a 
decrease in mean clearance (CL, mL/h/kg) and volume of distribution Vz (mL/kg). In addition, in in 
vitro study, high doses of IGU reduces the metabolism rate of diclofenac. IGU at high dose significantly 
increase the pharmacokinetics parameters of 4´-hydroxy diclofenac in rats. Additionally, it also showed 
the potent inhibitory effect on diclofenac metabolism in recombinant human CYP2C9 yeast cells.
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INTRODUCTION
Iguratimod (IGU or T614), a novel disease-
modifying antirheumatic drug (DMARD), used solely in 
Japan and China for the tratment of rheumatoid arthritis 
(RA). It is noteworthy that IGU shows a useful effect in 
RA patients with inadequate response to methotrexate 
(Ishiguro et al., 2013; Hara et al., 2014). After numerous 
oral doses of the IGU in healthy male subjects (25 mg for 
14 days), several metabolites were identified in the plasma, 
including M1 (deformaylated form), M2 (N-acetylated 
form), M3, M4 and M5 (6- phenoxy- hydroxylated form), 
of which M1 and M2 were recognized to be effective 
metabolites. IGU is metabolized by cytochrome P450 
(CYP) which results in the formation of M1 metabolite, 
irrespective of recombinant CYP isoforms studied in the 
absence or presence of reduced nicotinamide adenine 
dinucleotide phosphate (NADPH). Previous studies have 
suggested that the metabolism of M1 through N-acetyl 
transferase results in the formation of M2 metabolite, 
while M4 and/or M5 metabolites are formed from IGU 
metabolism by several other isoforms including CYP2C9, 
CYP1A2, and CYP3A4 (Yamaori et al., 2015). When 
manufacturing approval of IGU was granted in Japan, 
the directions specified that caution must be considered 
for the combined use of IGU with warfarin, established 
on the statement that IGU extended prothrombin time in 
rat’s co-administered warfarin. Subsequently, the benefit iD
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of the IGU in combination with warfarin has changed from 
precaution to contraindication. 
The health society of Japan studied in vitro inhibitory 
effect of the IGU in human liver microsomes (HLMs), 
which demonstrated that at 100 µM concentration the 
activity of IGU is inhibited by 50%, as described in a 
published report (Ruddy, Austen, 1975) (4). Owing to 
the inhibitory effect and maximum uncontrolled hepatic 
response concentration, the probability of interaction 
among IGU and CYP2C9 substrate drugs is inadequate 
as estimated. A previous report from Toyama Chemical 
CO, Ltd demonstrated that the inhibitory effect of 
CYP2C9 inhibitors varied depending on the substrate 
used. In this above study, tolbutamide used as a probe 
substrate for CYP2C9 (Hanatani et al., 2003; Kumar 
et al., 2006). Astonishingly, there was a 5-fold increase 
in Ki values for tolbutamide 4-hydroxylation than 
S-warfarin 7-hydroxylation, confirmed on one third of 
CYP2C9 inhibitors (Kumar et al., 2006). Thus, IGU 
showed inhibitory effect on CYP2C9, may vary between 
S-warfarin and tolbutamide.
Diclofenac (2-[2-(2,6-dichlorophenylamino) 
phenyl] acetic acid) is a broadly used non-steroidal anti-
inflammatory drug (NSAID) specified for the treatment of 
irritation, RA, osteoarthritis, ankylosing spondylitis and 
discomfort in circumstances such as stiffness and severe 
muscle pain (Small, 1989). Diclofenac is metabolized 
through oxidative biotransformation and glucuronidation in 
humans. Oxidative biotransformation of the aromatic ring 
is performed through cytochrome P450 and hydroxylation 
of the dichlorophenyl group is particularly catalyzed 
by CYP2C9 to form 4´-hydroxy diclofenac as the main 
metabolite, while glucuronidation of the carboxylic 
acid unit is mediated through uridine diphosphate 
glucuronosyltransferase (UGT) 2B7 (Leemann, Transon, 
Dayer, 1993). The CYP2C9 enzyme is responsible for 3´and 
4´-hydroxylation, whereas CYP2C and CYP3A4 enzymes 
mediate through 5´-hydroxylation (Leemann, Transon, 
Dayer, 1993; Bort et al., 1999) (Figure 1). Oxidation of 
numerous drugs i.e. diclofenac, flurbiprofen, warfarin, 
hexobarbital, phenytoin, and tolbutamide are structurally 
diverse substrates used recently, and their metabolism 
occurs mainly through CYP2C9 enzyme that is abundant 
in human liver microsomes (HLMs) (Goldstein, de Morais, 
1994; Tracy et al., 1996; Inoue et al., 1997; Miners, 
Birkett, 1998; Yamazaki et al., 1998). Diclofenac is used 
as the substrate for studies of CYP2C9 metabolic activity 
frequently because 4´-hydroxy diclofenac is metabolized 
through CYP2C9 (Mancy et al., 1999).
The aim of our study is to examine and analyse 
the effect of IGU on the metabolism of diclofenac in rats 
and estimate the diclofenac and 4-hydroxy diclofenac 
concentration in plasma by HPLC. In addition, we also 
investigate and explore the effect of IGU on human 
recombinant CYP2C9 yeast cells. We also elucidate 
the potential interaction between IGU and the CYP2C9 
substrate. The potential of in vitro interaction between 
IGU and UGT enzyme inhibition is additionally discussed.
MATERIAL
Instruments
LC-2010AHT High  Pe r fo rmance  L iqu id 
Chromatography (Shimadzu Co., Japan), a quaternary 
high-pressure pump, DAD UV detector, SHIMADZU Lab 
Solutions LC solution workstation.
Reagents
Acetonitrile of HPLC grade purchased from 
Merck KGaA, (Germany). Trifluoroacetic acid (purity: 
99%, batch number 150429824D). Bifendate reference 
standard (China Institute of pharmaceutical and biological 
products, purity: 99%, batch number: 100192-200503. 
4´-hydroxy-diclofenac reference standard (Nanjing BRT-
Biomed Co. Ltd. batch number 160105, purity: 99%). 
Diclofenac injection (Furen Pharmaceutical Group Co., 
Ltd. batch number 1404203, specification: 50mg/2ml). 
IGU (Xiansheng Co., Ltd. Batch number 42-160201, 
specification: 25 mg)
Animals
Several experimental trials were performed on 
24 male Sprague-Dawley (S.D.) rats, provided by the 
FIGURE 1 - Proposed primary metabolic pathways for 
diclofenac in humans.
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Shanghai Jie Esprit experimental animal Co. License 
number: SCXK 2013- 0006 (Shanghai, China), weighing 
approximately in the range of 180-220g. The twenty 
four rats were randomly divided into three groups (4 per 
cage) under normal lighting, temperature (25±2°C) and 
moisture. Afterward, rats from each group of rats was 
fasted overnight with free access to water and pellet 
food. The study was favored by the animal control and 
handling Agency of China Pharmaceutical University 
and was presented in agreement through the national 
institute of health guidelines for the control and handling 
of animals.
METHOD
Pharmacokinetic study of diclofenac and 
4-hydroxy diclofenac in rats
Experimental procedure
Twenty-four S.D. rats were randomly divided into 
three groups of eight animals in each group i.e. control 
group (normal saline 0.9%); low dose IGU group (10mg/
kg, p.o); high dose IGU group (30mg/kg p.o), rats were 
adaptive feeding for one week. Meanwhile, appropriate 
medicinal dose was administered twice a day for seven 
consecutive days. In this part of the experiment 1 hour 
before collecting of blood sample, diclofenac 15mg/kg iv 
bolus was given. Then the blood samples were collected 
in 2mL Eppendorf tubes containing sodium citrate as 
anticoagulant before and after diclofenac administration 
at 0.05, 0.15, 0.30, 0.45, 1, 1.5, 2, 3, 4, 6, 8, 10, 12 and 24 
h from orbital sinuses vein. Plasma separated by 5000 rpm 
centrifugation for 10min at 4°C, and stored at -20°C deep 
freezer until further experiments. HPLC technique was 
used to examine the plasma concentration of diclofenac.
Determination of diclofenac plasma 
concentration by HPLC method
Plasma sample preparation
Approximately 50μL plasma was added to a 1.5mL 
centrifuge tube, followed by 25μL (40mg/L) of internal 
standard Bifendate, 25μL of acetonitrile was combined 
and mixed for 2min in a vortex mixer and centrifuged at 
12000rpm, 4℃ for 10min. After this centrifuge mixture, 
take out the supernatant for HPLC analysis.
Chromatographic conditions
The chromatographic column expended for this 
analysis was Galaksil EF-C18H (250mm x 4.6mm, 5μm). 
The mobile phase is consist of acetonitrile: water (55:45, 
add 0.1% trifluoroacetic acid). The injection volume was 
10μL. The flow rate was controlled to 1.0ml/min and the 
emission was observed at 280nm. The entire run time of 
the system was fixed at 15min. 
Preparation of stock solutions
Standard solutions of 1mg/mL of diclofenac 
and 4´-hydroxy-diclofenac were made distinctly in 
methanol and kept at 4℃. Working standard solution 
were made by successively mitigating the stock 
solution using acetonitrile. The internal standard stock 
solution (bifendate, 40µg/mL) was made in acetonitrile. 
Calibration samples were made by adding mixtures of the 
standard combination with blank rat plasma to develop 
a concentration series of 0.25, 0.5, 1, 2, 5, 10, 20 and 40 
µg/mL for diclofenac and 4´-hydroxy diclofenac. Quality 
control samples of diclofenac and 4´-hydroxy diclofenac 
in different concentration were similarly organized in a 
related way. All solutions were kept at -20℃ previously 
consume. All samples remained collected at intervals for 
diclofenac bioanalysis and were stored frozen at -80℃ 
until examined.
Extraction technique
From plasma, the drug was obtained with acetonitrile. 
In a 1.5mL centrifuge tube, 50µL of plasma was put in. The 
plasma was triggered by the adjunct of 25µl of acetonitrile, 
and 25µL of bifendate internal standard, and then the tube 
was vortexed for 2min and centrifuged at 12000rpm, 
4℃ for 10min. The supernatant was moved to a sterile, 
similarly marked tube. The ensued mixture was vaporized, 
and reorganized with the mobile phase. From this sample, 
10µl was injected to HPLC.
Construction of calibration curve
The calibration curve was assembled using highest 
area against minimal concentration. According to 
diclofenac, 4´-hydroxy diclofenac and internal standard 
peak area ratio (y) of concentration (x) linear regression 
analysis was achieved respectively. The grade of the area 
controlled by the scheme of least-square regression assay 
exploited to estimate the diclofenac and 4´-hydroxyl 
diclofenac concentration in the unidentified sample. 
Determination of diclofenac metabolism rate in 
recombinant human CYP2C9 yeast cells by HPLC
The recombinant S. cerevisiae cells expressing 
human P450s were cultured in artificial minimal medium 
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comprising 40% glucose, sterile distilled water, 1M 
potassium Phosphate Buffer (pH 7.4), and then low, 
medium and high doses of IGU were added to the 
CYP2C9 yeast cells culture reaction system. When the 
cell concentration of culture reached 100mM/L, 2h before 
diclofenac in dimethyl sulfoxide (DMSO) was adjoined 
to the system at a final concentration of 1000µM. At 
24h after addition of diclofenac, 100µL of the culture 
were obtained with 200µL of methanol and centrifuged 
at 12000×g for 10min. The subsequent filtrate was 
solubilized with methanol and operated to HPLC under 
the subsequent circumstances: column, Galaksil EF-C18H 
(250mm x 4.6mm, 5μm); UV detection, 280nm; flow 
rate, 1.0mL/min; column temperature, 40 °C; injection 
volume, 10µL; and the mobile phase consisted of water: 
acetonitrile (containing 0.1% trifluoroacetic acid) at 45:55. 
The inhibitory response rate of diclofenac metabolism in 
human recombinant CYP2C9 yeast cells were calculated 
using the formula.
Statistical analysis
All statistics were calculated using IBM SPSS 
statistics version 22. The PK parameters were calculated 
using WinNonlin non-compartmental model (Pharsight 
Co, Mountain View, CA, and the USA. 6.0). The PK 
parameters of diclofenac and 4-hydroxy diclofenac for 
groups were compared by means of one-way ANOVA 
pursued by Games-Howell Post Hoc test. The in vitro 
inhibitory study for diclofenac were also analyzed by the 
same test above. The p<0.05 were considered significant.
RESULTS
Assessment of diclofenac and 4-hydroxy 
diclofenac in plasma samples by HPLC
By analyzing blank plasma samples the selectivity 
of HPLC analysis was studied, which did not display any 
interfering components (Figure 2A). The entire run time 
of the technique was established at 15min. Retention time 
was 11.26min and 5.22min for diclofenac and 4´-hydroxy 
diclofenac respectively (Figure 2). 
The linear regression analysis of diclofenac and 
4´-hydroxy diclofenac was formed by calculating the 
peak-area ratio of diclofenac, 4´-hydroxy diclofenac and 
internal standard. The method displays excellent linearity 
over a concentration range of 0.25-40µg.mL-1 for both 
diclofenac and 4´-hydroxy diclofenac (y = 0.1083x + 
0.0014, r = 0.999, n=6; y=0.043x + 0.0013, r = 0.999, 
n=6) respectively. The limit of detection for diclofenac 
and 4´-hydroxy diclofenac was 0.15μg.mL-1.
In accordance with the method of preparation 
containing diclofenac (0.5, 10,40μg / mL) and 4´-hydroxy 
diclofenac (0.5, 10,40μg /mL) plasma samples, there 
are good intra- and inter-day precision (RSD<5%, n=3) 
respectively (Table I).
FIGURE 2 - HPLC profiles of diclofenac and its metabolite 4-hydroxy diclofenac in rats and in human recombinant CYP2C9 yeast 
cells. A. Blank plasma; B. Blank plasma spiked with reference substance; C. Sample before administration of diclofenac; D. Sample 
15min after administration of Diclofenac+Bifendate. 1. 4’-hydroxydiclofenac 2. Bifendate 3. Diclofenac.
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Effect of iguratimod on the pharmacokinetics of 
diclofenac and 4´-hydroxy diclofenac in rats
The plasma concentration-time profile for diclofenac 
and 4´-hydroxy diclofenac given with IGU at low and 
high dose are shown in Figure 1. The pharmacokinetic 
parameters such as area under the curve (AUC), half-life 
(T1/2), volume of distribution (Vz) clearance (CL) for 
diclofenac and 4´-hydroxy diclofenac at control, low and 
high dose are summarized in Table I and II for in vivo study. 
The PK parameters of diclofenac plasma concentration 
when co-administered with IGU at low and high dose 
does not show any considerable changes associated with 
the control (P >0.05, Table II). Similarly, at low dose IGU 
and 4´-hydroxy diclofenac does not show any significant 
differences compared with control (p>0.05). However, the 
4´-hydroxy diclofenac showed significant differences at the 
high dose of IGU compared with control (p<0.001).
In this study, the mean T1/2 for 4´-hydroxy diclofenac 
significantly increased from 13.56±7.05 to 28.84±15.95 
(p>0.05); mean AUC0-24 increased from 9.92±2.78 to 
47.14±11.75 (p<0.001); mean CL (mL/h/kg) decreased 
from 1.17±0.35 to 0.16±0.06 (p<0.001); also Vz (ml/kg) 
decreased from 20.98±7.96 to 5.95±1.67 (p<0.01) at high 
dose i.e., 30mg/kg. (Table III)
Effect of iguratimod on the metabolism of 
diclofenac in recombinant human CYP2C9 yeast 
cells
The in vitro study was carry out in recombinant 
human CYP2C9 yeast cell system. There was no 
significant interaction at low and medium doses of IGU 
(p>0.05). However, the high dose of IGU significantly 
decreased in an inhibitory response rate of diclofenac 
from 32.33±8.58% to 12.01±4.77% (p<0.001, Table IV).
DISCUSSION
G e n e r a l l y,  t h e r e  a r e  t w o  t y p e s  o f  d r u g 
interaction studies such as pharmacokinetics (PK) and 
pharmacodynamics (PD). Between PK interactions, the 
CYPs in the gut wall and liver, as well as the drug carrier, 
i.e. P-glycoprotein plays a major part, however also other 
enzymes and transport systems might be concerned. 
CYP enzymes are essential for the clearance of distant 
substances and breakdown of drugs. Nearly there are 
more than 50 CYP enzymes, but the CYP1A2, CYP2C9, 
CYP2C19, CYP2D6, CYP3A4, and CYP3A5 enzymes 
metabolize 90% of drugs available in the market. These 
enzymes primarily expressed in the liver, they additionally 
TABLE I - Intra and Inter-day precision of diclofenac and 4′-hydroxydiclofenac (n=3)
Sample concentration 
(C/μg·mL-1)
Mean concentration ± 
SD (C/μg·mL-1) Intra-day RSD/% Inter-day RSD/%
Diclofenac
0.5 0.466±0.015 3.19 3.19
5 5.05±0.12 2.46 0.83
40 39.78±0.14 0.35 0.60
4′-hydroxydiclofenac
0.5 0.469±0.020 3.19 4.35
5 5.10±0.10 1.90 0.45
40 39.85±0.21 0.52 0.64
TABLE II - Comparison of pharmacokinetics parameters of diclofenac in the presence of iguratimod
Parameters Control DA Low Dose  IG (10 mg/kg) +DA
High Dose 
IG (30 mg/kg) +DA
T1/2 5.81±1.56 7.79±4.37 9.92±4.20
AUC0→24h 35.08±9.3 32.66±5.73 43.80±10.95
CL (mL/h/kg) 0.43±0.11 0.44±0.08 0.33±0.10
Vz (mL/kg) 3.64±1.43 4.77±2.37 4.57±1.65
DA, diclofenac; IGU, iguratimod; T1/2, half-life; AUC0→24h, area under the curve; CL, clearance; Vz, the volume of distribution. 
All values are Mean±SD. *** p<0.001, ** p<0.01, * p<0.05 when compared to the normal saline group (one way ANOVA followed 
by Games Howell test to compare to each column to column) 
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TABLE III - Comparison of pharmacokinetics parameters of 4 hydroxy diclofenac in the presence of iguratimod
Parameters Control OHDA Low Dose  
IG (10 mg/kg)+OHDA
High Dose 
IG (30 mg/kg)+OHDA
T1/2 13.56±7.05 12.05±3.81 28.84±15.95
AUC0→24h 9.92±2.78 13.12±2.62 47.14±11.75***
CL (mL/h/kg) 1.17±0.35 0.94±0.27 0.16±0.06***
Vz (mL/kg) 20.98±7.96 15.79±4.95 5.95±1.67**
DA, diclofenac; IGU, iguratimod; OHDA, 4-hydroxy diclofenac; T1/2, half-life; AUC0→24h, area under the curve; CL, clearance; 
Vz, the volume of distribution. All values are Mean±SD (n=8). *** p<0.001, ** p<0.01, * p<0.05 when compared to the normal saline 
group (one way ANOVA followed by Games Howell test to compare to each column to column) 
TABLE IV - Inhibitory Effect of Iguratimod on Diclofenac metabolism in human recombinant CYP2C9 yeast cells
Groups Control group Low Dose group 
(0.25 mM/L) 
Medium dose group 
(0.5 mM/L)
High Dose group 
(1 mM/L)
Inhibitory response rate (%) 32.33±8.58 37.80±5.96 33.94±5.28 12.01±4.77***
All values are Mean±SD (n=8). DA: diclofenac. *** p<0.001, ** p<0.01, * p<0.05 when compared to the normal saline group (one 
way ANOVA followed by Games Howell test to compare to each column to column)
appear in the kidneys, small intestine, placenta and lungs 
(Slaughter, Edwards, 1995; Wilkinson, 2005).
In the current study, we examined and analysed 
the effect of IGU on the pharmacokinetics of diclofenac 
and 4´-hydroxy diclofenac in rats. Furthermore, we also 
examined the inhibitory effects of IGU on diclofenac 
in recombinant human CYP2C9 yeast cell system. 
Our investigation showed that there was no significant 
interaction between low dose IGU and diclofenac both 
in vivo and in vitro studies (p>0.05). However, at higher 
doses i.e. 30mg/kg IGU significantly increased the plasma 
concentration of 4´-hydroxy diclofenac but did not 
increase diclofenac plasma concentration as compared 
with the control group in rats (Table III, Figure 2). 
Moreover, at high dose, IGU significantly inhibited the 
metabolism of diclofenac in vitro (Table IV). These results 
give a possible direction that IGU may not directly show 
an inhibitory effect on the activity of CYP2C9 in vivo. 
However, we suggest that IGU or its metabolites might 
show inhibitory effect on glucuronidation of 4´-hydroxy 
diclofenac to form 4´-hydroxy diclofenac glucuronide. 
Toyama Chemical Co., Ltd. has conducted inhibition 
studies on metabolites of IGU previously, the metabolites 
of IGU, i.e., M1, M2, M3, M4, and M5, at a dilution 
of 100μM inhibited tolbutamide 4-hydroxylase action 
of HLMs by 34.3%, 44.9%,19.3%, 29.3%, and 29.1%, 
correspondingly. Between these metabolites, M4 is 
formed precisely from IGU by numerous CYP isoforms, 
including CYP2C9. These findings suggest that IGU 
metabolites, such as M2, which demonstrate a noteworthy 
inhibitory effect on CYP2C9 action, is equivalent to that 
of IGU (Taisho Toyama Pharmaceutical Co., 2013). As the 
maximum complete plasma concentration of M2 regarding 
frequent oral administration of IGU is nearly 2- folds 
greater than that of IGU (Taisho Toyama Pharmaceutical 
Co., 2013). It is likely that M2 as well as IGU play 
an essential part in inhibition of CYP2C9-facilitated 
diclofenac metabolism, which might reinforce by our 
outcomes of our in vitro study. However, there is no direct 
indication that IGU metabolites, including M2, inhibit 
diclofenac metabolism. Advanced studies are needed to 
describe the inhibitory effects of IGU metabolites. Our 
results indicate that at high dosage of IGU the mean T1/2 
of 4´-hydroxy diclofenac increased by 212% (p> 0.05), 
increase the mean AUC by 475% (P< 0.001), and decrease 
clearance by 13% (p< 0.001), with the control group in 
the in vivo study. These results suggest that IGU or its 
metabolites may play an inhibitory effect on UGT enzyme 
that metabolizes the 4´-hydroxy diclofenac to 4´-hydroxy 
diclofenac glucuronide.
Diclofenac is an efficient and commonly approved 
NSAIDS, that is metabolized by numerous drug 
metabolizing routes, including cytochrome P450s 
(CYPs) and uridine 5-diphosphoglucuronosyl transferase 
(UGTs) (King et al., 2001). The general metabolic route 
of diclofenac to form 4-hydroxy diclofenac is catalyzed 
primarily by CYP2C9, which is distinguished to reveal a 
naturally controlled polymorphism causing in changed 
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pharmacokinetic and pharmacodynamic properties of 
certain clinically significant drugs (Yu et al., 2005). While 
human UGT2B7 and rat UGT2B1 is the main enzyme 
concerned in catalyzing the glucuronidation of diclofenac 
in HLMs and rats (Wei, 2003). The in vitro inhibitory effect 
of IGU was studied in HLMs, as explained in an article 
issued by the agency of health, labor and safety Japan, 
that IGU at a concentration of 100µM inhibits CYP2C9 
action by 50% (Ruddy, Austen, 1975). In our in vitro study, 
high doses of IGU significantly inhibited the diclofenac 
metabolism in the recombinant human CYP2C9 yeast cell 
culture system, its metabolism rate is decreased by 37% 
compared with the control phase (Table III). Our data 
estimated that diclofenac is metabolized by CYP2C9, and 
IGU inhibits the CYP2C9 activity in recombinant human 
CYP2C9 yeast cells. The hypothesis described above 
have suggested predominantly on in vitro study in which 
oxidative metabolism is the single choice existing for the 
substrate, while various pathways may subsist in in vivo 
for metabolism of diclofenac in the liver.
Several CYP2C9 inhibitors exhibit substrate-
dependent inhibitory effects (Hanatani et al., 2003; Kumar 
et al., 2006). Kumar et al. (2006) observed the inhibitory 
relationship of 28 complexes with five often functioned 
in vitro probe substrates for CYP2C9. Diclofenac used as 
the comparator (it is a probe for CY92C9 most frequently 
used), once the inhibition of every compound competed 
for the additional substrates, inhibitors of (S)-warfarin 
metabolism indicated the highest amount of variations 
arrangement in both CYP2C9.1 and CYP2C9.3 enzymes. 
FIGURE 3 - Mean plasma concentration-time profile of diclofenac and 4´-hydroxy diclofenac with iguratimod in rats. The 
concentration of diclofenac (A) and 4-hydroxy diclofenac (B) in plasma were plotted against the time after administration of 
15 mg/kg diclofenac and IGU at normal saline (), low IGU 10 mg/kg () and high IGU 30 mg/kg (). Each value represents 
the mean±S.D. of eight animals each. (A) Diclofenac (B) 4’-hydroxydiclofenac.
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Twelve inhibitors of CYP2C9.1 and ten inhibitors of 
CYP2C9.3 when (S) warfarin was used as a substrate 
probe turn out to be considered as ensuing of more 
interest. Eight inhibitors of the 12 in CYP2C9.1 and 
four inhibitors of CYP2C9.3 shifted from the average 
of the highest concern category, as matched with when 
diclofenac was exploited as the probe. Thus, the substrate 
probes dropped into three separate divisions varying in 
genotype, proposing that several probes could be required 
to completely evaluate inhibition of CYP2C9 in vitro. A 
pattern of inhibition studies using diclofenac and (S)-
warfarin might give the widest ‘biochemical space’ in 
particular to CYP2C9 inhibition (Kumar et al., 2006).
CONCLUSION
The results demonstrate that IGU at low dose shows 
no inhibitory effect on the pharmacokinetic parameters of 
diclofenac and 4-hydroxy diclofenac in rats; also at a low 
dose, it shows no inhibitory effect on the metabolism of 
diclofenac in human recombinant CYP2C9 yeast cells. 
However, at high dose, IGU shows a major variation in 
pharmacokinetics parameters of 4´-hydroxy diclofenac in 
rats, as well as it shows a direct inhibition of diclofenac 
metabolism in human recombinant CYP2C9 yeast cells. 
Beside this, our study also gives a possible direction 
that IGU or its metabolites may inhibit UGT mediated 
metabolism of 4´-hydroxy diclofenac to form 4´-hydroxy 
diclofenac glucuronide. Nevertheless, mechanism based 
inhibition of UGT enzyme by IGU metabolites and well-
controlled scientific studies needed to verify the effect of 
IGU or its metabolites on CYP2C9 and UGT.
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